Cheetah prospects - whether it is the best thing since sliced bread or not - one thing is for sure - Halo won't be able to afford to carry out a Phase 3 trial on its own. The number of patients that the FDA would demand would be too daunting for a small biotech. So unless they can find a partner this program won't be progressing in-house. They seem to have pinned their hopes 100% on Eli Lilly with the HumulinR and Humalog trials. If Lilly tell them to take a walk then where do they go? Having said that I'm delighted with the Roche news and can see that acting as a major spur for other biologic pharmas to come on board. I guess thats why the share price has been so strong over the past couple of days - something that has not even been mentioned on this Board - come on guys - wake up! So the external programs could be fantastic - lets hope that the management don't spend all the proceeds on no-hope in-house programs. I'm yet to be convinced on those. As another poster said recently the management do seem to unable to concentrate their efforts on one or two programs. Are they spreading the net too wide? A bird in the hand ....
Market Data 
Markets 
AI
